Introduction
============

The past two decades have witnessed great progress on the research regarding optimal glycemic control strategy for critically ill patients based on several randomized controlled trials (RCTs). However, there are still debates on this topic. Numerous studies have reported that dysglycemia including hyperglycemia, hypoglycemia or serum blood fluctuation is an independent risk factor of mortality for critically ill patients, especially for those with diabetes mellitus ([@bib1], [@bib2], [@bib3], [@bib4]).

In 2001, Berghe and his colleagues found that intensive glucose control (IGC) could significantly reduce the mortality for surgical patients with mechanical ventilation ([@bib5]). Since then, IGC has become a general practice for those critically ill patients. However, several other clinical trials reported the neutral effects of IGC for these patients ([@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]). Moreover, one of the most famous trials, the Normogylcemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial ([@bib12]), found that IGC increased mortality among adults in the intensive care unit (ICU), which could potentially result from the increased incidence of hypoglycemia based on a *post hoc* analysis of the same trial ([@bib13]). Evidence also demonstrated that severe hypoglycemia was strongly associated with hospital mortality, which was considered as an interactive factor for mortality ([@bib3], [@bib14], [@bib15]). With all those dubious results, we aimed to reassess the existing uncertain evidence regarding this issue using the systematic review and meta-analysis of all published literature.

Methods
=======

Literature search
-----------------

We performed the meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement ([@bib16]). Primary sources of the reviewed studies, including PubMed, EMBASE and the Cochrane Library were systematically searched for citations from initials through December 2017. The following words were searched through the combinations of the keywords and text words: (ICU OR intensive care unit OR intensive care OR critical care OR critical illness OR postoperative care OR cardiac care facility\* OR coronary care OR recovery room OR burn unit OR critically ill OR cardiac care OR cardiac care unit OR CCU) AND (insulin OR blood glucose OR intensive insulin OR glycemic control) AND (randomized OR randomised OR placebo OR randomly OR trial). Three reviewers (F S M, M M and S P) independently conducted online database searches and manual searches of reference lists from potentially eligible articles. The search strategies for the three databases were provided in Supplementary Methods (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article).

Eligibility criteria
--------------------

RCTs evaluating the effects of IGC with conventional glucose control for the management of adult critically ill patients were eligible for inclusion. We involved trials reporting the outcomes like short-term mortality (in-hospital mortality or ICU mortality) or 3- to 6-month mortality, risk of hypoglycemia, sepsis and new need for dialysis.

Trials that did not include the above mentioned outcomes or have sufficient data to calculate effect estimates were excluded from meta-analysis. Three investigators (Y F, Y S and J Z) independently conducted trial selection. When overlapping trials were included, only the largest one with the most comprehensive data or analyses was involved.

Data extraction
---------------

Three authors (Y F, Y S and J Z) independently extracted data on relevant variables from all trials using a predesigned standardized abstraction form, which were cross-checked and finally determined by a third author (Y C). Study-level data included first author, publication year, ICU type, sample size patient disease, patient age, percent of the diabetes cases, follow-up duration, intervention, daily insulin dose, target blood glucose level, achieved blood glucose level and outcome reported. The corresponding authors of original articles were contacted for missing data if necessary.

Trial bias assessment
---------------------

Two authors (Y F and Y C) independently assessed trial bias of each included trial using the Cochrane collaboration's tool ([@bib17]). This validated scale covered three aspects to assess the methodological bias in terms of random allocation, double-blinding and withdrawals and dropouts for intervention or control groups, with higher scores representing lower risk of bias.

Outcome definitions
-------------------

The primary outcomes were 3- to 6-month mortality and short-term mortality. The former was defined as in hospital mortality or ICU mortality, mainly within 28-day mortality. When both in-hospital mortality and ICU mortality were reported in the same trial, we selected in hospital mortality as 3- 6-month mortality. The latter was defined as mortality at the time of 3 and 6 months. The secondary outcomes included risk of hypoglycemia, sepsis and new need for dialysis. Hypoglycemia was defined as patients with serum glucose level less than 2.2 mmol/L or 40 mg/dL. Sepsis was defined as patients who were diagnosed as sepsis, septicemia, bacteremia or having positive blood cultures. We defined new need for dialysis as patients who required dialysis because of renal failure for the first time.

Data synthesis
--------------

The result of each trial outcome was allocated as dichotomous variable. All analyses were based on data reported as intention to treat. A *P* value less than 0.05 was considered as significant difference. Considering the clinical (patient demographics and treatment strategy), methodological (randomization or outcome reported) and statistical (sample size) heterogeneity among included trials, we have applied random-effect model to combine effect estimates. Summary RRs and the corresponding 95% CIs were calculated and compared with a DerSimonian and Laird random-effects model, a method accounting for both within-study variance and between-study heterogeneity. Between-study heterogeneity was assessed by *Q* test and quantified by *I* ^2^ statistic and with an *I* ^2^ value being less than 0.10 considering statistically significant ([@bib18]). Furthermore, we conducted pre-planned subgroup analyses for all the five outcomes based on the clinical variables available to investigate the potential sources of heterogeneity. Sensitivity analyses were also performed by omitting a single trial each time and recalculating the effect estimates to investigate the robustness of our summary statistics. The presence of publication bias was evaluated by using the Begg's test and Egger's test besides funnel plot symmetry ([@bib19], [@bib20]). The Duvall and Tweedle trim-and-fill model was used to adjust effect estimates ([@bib21]). All meta-analyses were performed and figures were generated in Stata, version 14.0 (StataCorp).

Results
=======

Twenty-seven trials ([Fig. 1](#fig1){ref-type="fig"}), including 17,582 patients, assessed the effect of IGC therapy (IGC therapy vs conventional glucose control therapy) in patients with critical surgical or medical illness ([@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib22], [@bib23], [@bib24], [@bib25], [@bib6], [@bib7], [@bib8], [@bib9], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib6], [@bib7], [@bib8], [@bib9], [@bib40], [@bib41]). Detailed clinical characteristics of the trials are reported in [Table 1](#tbl1){ref-type="table"}. IGC therapy was conducted in surgical ICUs in eight trials, five medical ICUs and fourteen surgical mixed with medical ICUs. The median sample size of the included trials was 240 (range, 20--6104). The mean percent of diabetic patients was 22%. The two intervention procedures for most of trials were insulin infusion and subcutaneous insulin injection. Target blood glucose level ranged from less than 6.9--12.5 mmol/L in trial group and within 4.4--6.1 mmol/L (*n* = 25) or 6.1--8.3 mmol/L (*n* = 2) in the control group. Moderate to higher risk of bias was found due to inappropriate double-blinding method of trial design for most of the trials (data provided upon request).Figure 1Flow chart of included articles selected for inclusion in the meta-analysis. Table 1Characteristics of the included trials.StudyYearICU typeSample sizePatient diseaseMean age, yearDiabetes, %Follow-up durationInterventionMean daily insulin dose, IU/dayTarget blood glucose level, mmol/LAchieved blood glucose level, mmol/LOutcomes included in meta-analysisWang *et al.*2017Surgical88Traumatic brain injuryTG 46.7; CG 45.119.36 monthsBoth groups: insulin infusionNACG: \<11.11 TG: 4.4--6.1NAMortalityFinfer *et al.*2015Mixed391Operative: TG 80, CG 75; Non-operative: TG 123, CG 113TG 41.9; CG 41.25.42 yearsBoth groups: insulin infusionCG: 7.6 TG: 52.8CG: \<10.0 TG: 4.5--6.0Mean BG CG: 7.7 TG: 7.7Mortality, hypoglycemia, new need for dialysis, sepsisKalfon *et al.*2014Mixed2648Surgical (emergency): TG 417, CG 380; Surgical (scheduled): TG 121, CG 141; Nonsurgical: TG 798, CG 791; Polytrauma: TG 91, CG 85TG 61; CG 62TG 19.6; CG 20.990 daysBoth groups: insulin infusionMedian dose TG: 43.1 CG:34.1CG: ≤10.0 TG: 4.4--6.1Mean BG CG: 9.1 TG: 9.4Mortality, hypoglycemia, sepsisOkabayashi *et al.*2014Surgical447Hepato-biliary pancreatic diseasesTG 66.7; CG 66.427.1Hospital stayBoth groups: insulin infusionCG: 77 TG: 101CG: 7.7--10.0 TG: 4.4--6.1NAMortalityZuo *et al.*2012Mixed30Medical: severe acute pancreatitis480Hospital stayCG: subcutaneous insulin injection TG: insulin infusionCG: 32.4 TG: 71.4CG: 10--11.1 TG: 6.1--8.3Mean BG CG: NA TG: 7.46MortalityCao *et al.*2011Surgical179Gastric cancer, 10058.810028 daysBoth groups: insulin infusionNACG: 10--11.0 TG: 4.4--6.1Mean BG CG: 9.9 TG: 5.5Mortality, hypoglycemia, sepsisArabi *et al.*2011Mixed240Medical: m83 Surgical: m1751.140180 daysBoth groups: insulin infusionCG: 23 TG: 62.8CG: 10--11.1 TG: 4.4--6.1Mean BG CG: 8.6 TG: 6.2Mortality, hypoglycemia, new need for dialysis, sepsisCoester *et al.*2010Surgical88Severe traumatic brain injury, 10038.51.26 monthsCG: subcutaneous insulin injection TG: insulin infusionNACG: \<10 TG: 4.4--6.1Mean BG CG: 8.06 TG: 6.85Mortality, hypoglycemia, sepsisGreen *et al.*2010Medical81Ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, 35; traumatic brain injury, 4951NA90 daysCG: subcutaneous insulin injection TG: insulin infusionCG: 1.4 IU/h TG: 2.39 IU/hCG: ≤8.3 TG: 4.4--6.1Mean BG CG: 7.9 TG: 6.2Mortality, hypoglycemia, sepsisAnnan *et al.*2010Mixed509Medical: 75 Surgical: 1164NA180 daysCG: subcutaneous insulin injection TG: insulin infusionCG: 46 TG: 71 (median)CG: not defined TG: 4.4--6.1NAMortality, hypoglycemiaBilotta *et al.*2009Surgical483Neurosurgery, 10057.1106 monthsBoth groups: insulin infusionCG: 21 TG: 54CG: \<11.94 TG: 4.44--6.11Mean BG CG: 7.96 TG: 5.13Mortality, sepsisYang *et al.*2009Surgical240Severe traumatic brain injury, 10045.5106 monthsBoth groups: insulin infusionNACG: 10--11.1 TG: 4.4--6.1NAMortality, hypoglycemiaCavalcanti *et al.*2009Medical112Respiratory, 32; sepsis, cardiovascular, neurologic, 4459.93090 daysCG: subcutaneous insulin injection TG: insulin infusionNACG: \<8.3 TG: 4.4--6.1Median BG CG: 8.8 TG: 7.1HypoglycemiaKreisel *et al.*2009Medical40Acute ischemic stroke, 10071.633120 daysCG: subcutaneous insulin injection TG: insulin infusionCG: 5.4 TG: 13.3CG: \<11.1 TG: 4.44--6.11Mean BG CG: 8.01 TG: 6.49MortalityFinfer *et al.*2009Mixed6104Medical: 62 Surgical: 3862.22090 daysBoth groups: insulin infusionCG: 16.9 TG: 50.2CG: \<10 TG: 4.5--6.0Mean BG CG: 8.0wTG: 6.4Mortality, hypoglycemia, new need for dialysis, sepsisPreiser *et al.*2009Mixed1101Medical: 40 Surgical: 47 Trauma: 1364.618Hospital stayBoth groups: insulin infusionMedian rate CG: 0.32 IU/h TG: 1.30 IU/hCG: 7.8--10.0 TG: 4.4--6.1Median BG CG: 8.0 TG: 6.5Mortality, hypoglycemiaTaslimi *et al.*2009Mixed129Medical: 75 Surgical: 2555.553Hospital stayBoth groups: insulin infusionNRCG: 6.9--12.5 TG: 4.4--6.1NAMortality, new need for dialysisSavioli *et al.*2009Mixed90Medical: 62 Surgical: 38611390 daysBoth groups: insulin infusionCG: 36 TG: 57CG: 10--11.1 TG: 4.4--6.1Mean BG CG: 8.8 TG: 6.2MortalityArabi *et al.*2008Mixed523Medical: 83 Surgical: 1752.440Hospital stayBoth groups: insulin infusionCG: 31.4 TG: 71.2CG: 10--11.1 TG: 4.4--6.1Mean BG CG: 9.5 TG: 6.4Mortality, hypoglycemia, new need for dialysis, sepsisBrunkhorst *et al.*2008Mixed537Sepsis Medical: 47 Surgical: 5364.63090 daysBoth groups: insulin infusionCG: 5 TG: 32 (median)CG: 10--11.1 TG: 4.4--6.1Mean morning BG CG: 8.4 TG: 6.2Mortality, hypoglycemia, new need for dialysisDe La Rosa *et al*.2008Mixed504Medical: 49 Surgical: 16 Trauma: 3546.612Hospital stayBoth groups: insulin infusionCG: 12.5 TG: 52.4CG: 10--11.1TG: 4.4--6.1Median morning BG CG: 8.2 TG: 6.5Mortality, hypoglycemia, new need for dialysisIapichino *et al.*2008Mixed90Sepsis Medical: 64 Surgical: 3262.31790 daysBoth groups: insulin infusionCG: 38.8 TG: 74.5CG: 10--11.1 TG: 4.4--6.1Mean BG CG: 9.0 TG: 6.1Mortality, hypoglycemiaOksanen *et al.*2007Medical90Out of hospital ventricular fibrillation, 10063.71230 daysBoth groups: insulin infusionCG: 12.5 TG: 22CG: 6.0--8.0 TG: 4.0--6.0Median BG CG: 6.4 TG: 5.0Mortality, hypoglycemiaMitchell *et al.*2006Mixed70Medical: 61 Surgical: 3 965.414Hospital stayBoth groups: insulin infusionCG: 0 TG: 35.7 (median)CG: 10--11.1 TG: 4.4--6.1Median BG CG: 7.9 TG: 5.4Mortality, hypoglycemiaHoedemaekers *et al.*2005Surgical20CABG, 10064.20Hospital stayBoth groups: insulin infusionNACG: \<11.1 TG: 4.4--6.1NAHypoglycemiaVan den Berghe *et al.*2001Surgical1548Cardiac surgery, 6362.813Hospital stayBoth groups: insulin infusionCG: 33 TG: 71CG: 10--11.1 TG: 4.4--6.1Mean morning BG CG: 8.5 TG: 5.7Mortality, hypoglycemia, new need for dialysis, sepsisVan den Berghe *et al.*2001Medical1200Respiratory, 42.7; gastrointestinal, liver, 25.563.51790 daysBoth groups: insulin infusionCG: 10 TG: 59CG: 10--11.1 TG: 4.4--6.1Mean morning BG CG: 8.49 TG: 6.16Mortality, hypoglycemia, new need for dialysis, sepsis[^1]

Results of meta-analyses, sensitivity analyses and publication bias assessment
------------------------------------------------------------------------------

### 3--6 month mortality

The data for the risk of 3- to 6-month mortality were available in 14 trials. The summary RR was 1.02 (95% CI, 0.97--1.08; *P* = 0.374). There was no evidence of heterogeneity (*I* ^2^ = 0; *P* = 0.619) ([Fig. 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Subgroup analyses indicated that for different ICU types of surgical, medical and mixed ICUs, the pooled RRs were 0.96 (95% CI, 0.81--1.13), 0.98 (95% CI, 0.84--1.16) and 1.04 (95% CI, 0.95--1.12), respectively, which was consistent with the result of the main analysis. Excluding one study at a time did not significantly alter the summary RR (Supplementary Fig. 1 and Supplementary Table 6). There was no evidence of publication bias using the Egger's test (*P* = 0.847) or Begg's test (*P* = 0.101) (Supplementary Table 1).Figure 2Forest plots comparing the effects of intensive glucose control on the risk of 3- to 6-month mortality with that of conventional glucose control. Table 2Subgroup analyses for effects of intensive glucose control on the risk of 3--6 month mortality for critically ill patients stratified by covariates.Stratification covariatesRR95% CIHeterogeneity (*I*^2^ statistics; %)No. of included studies*P* for interactionTotal1.030.97--1.090140.307Trial setting0.517 Surgical ICU0.960.81--1.1304 Medical ICU0.980.84--1.161.63 Mixed ICU1.040.95--1.1218.57Trial year0.074 Year 2001--20091.060.99--1.1309 Year 2010--20171.020.97--1.0805Study region0.615 America1.260.76--2.0702 Europe0.970.90--1.0507 Asia0.970.82--1.1603Sample size0.477 ≥5001.020.94--1.1140.45 \<5000.980.84--1.1309Patient mean age0.325 ≥601.030.98--1.09010 \<600.940.78--1.1304Diabetes, %0.435 ≥301.100.91--1.3103 \<301.020.96--1.07010Mean/median daily insulin dose0.257 ≥50 IU/day1.050.98--1.1308 \<50 IU/day1.010.87--1.1727.33[^2]

### Short-term mortality

Twenty trials reported the data regarding IGC and the risk of short-term mortality. The pooled RR was 0.99 (95% CI, 0.92--1.06; *P* = 0.741). There was low evidence of heterogeneity (*I* ^2^ = 15.8%; *P* = 0.257) ([Fig. 3](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). Subgroup analyses revealed that the summary RRs for surgical, medical and mixed ICUs were 0.82 (95% CI, 0.63--1.05), 0.99 (95% CI, 0.84--1.17) and 1.01 (95% CI, 0.94--1.10), respectively, which was in accord with the result of the main analysis. Sensitivity analysis did not significantly change the summary RR (Supplementary Fig. 2 and Supplementary Table 7). No evidence of publication bias was detected using the Egger's test (*P* = 0.975) or Begg's test (*P* = 0.871).Figure 3Forest plots comparing the effects of intensive glucose control on the risk of short-term mortality with that of conventional glucose control. Table 3Subgroup analyses for effects of intensive glucose control on the risk of short-term mortality for critically ill patients stratified by covariates.Stratification covariatesRR95% CIHeterogeneity (*I*^2^ statistics; %)No. of included studies*P* for interactionTotal0.990.94--1.0515.8200.826Trial setting0.134 Surgical ICU0.820.63--1.0513.56 Medical ICU0.990.84--1.1702 Mixed ICU1.010.94--1.1014.512Trial year0.313 Year 2001--20091.000.90--1.1026.412 Year 2010--20170.960.87--1.0608Study region0.301 America1.130.90--1.0302 Europe0.960.88--1.041.98 Asia0.900.75--1.081.18Sample size0.896 ≥5000.980.90--1.0742.88 \<5001.010.83--1.23012Patient mean age0.644 ≥600.980.90--1.0615.815 \<601.050.87--1.2705Diabetes, %0.360 ≥300.920.78--1.0905 \<300.990.89--1.0930.814Mean/median daily insulin dose0.281 ≥50 IU/day1.010.90--1.1337.711 \<50 IU/day0.960.83--1.1032.55[^3]

Risk of hypoglycemia
--------------------

The data for the risk of hypoglycemia were available in 19 trials. The summary RR was 4.86 (95% CI, 3.16--7.46; *P* \< 0.001) with significant heterogeneity (*I* ^2^ = 76.1%; *P* \< 0.001) (Supplementary Fig. 6 and Supplementary Table 2), indicating patients with IGC had almost 4-fold increase in risk of hypoglycemia. Subgroup analyses indicated that for different ICU types of surgical, medical and mixed ICUs, the pooled RRs were 3.90 (95% CI, 1.60--9.49), 6.03 (95% CI, 3.89--9.34) and 5.07 (95% CI, 2.80--9.18), respectively, which was consistent with the result of the main analysis. Sensitivity analysis by excluding one study at a time indicated the robustness of the pooled result (Supplementary Fig. 3 and Supplementary Table 8). There was no evidence of publication bias using the Egger's test (*P* = 0.149) or Begg's test (*P* = 0.726).

Risk of sepsis
--------------

Thirteen trials provided the data regarding analysis of IGC and the risk of sepsis. The pooled RR was 1.00 (95% CI, 0.89--1.11; *P* = 0.973). There was low evidence of heterogeneity (*I* ^2^ = 19.8%; *P* = 0.243) (Supplementary Fig. 7 and Supplementary Table 3). Subgroup analyses found that the pooled RRs for surgical, medical and mixed ICUs were 0.79 (95% CI, 0.42--1.48), 0.62 (95% CI, 0.22--1.72) and 1.03 (95% CI, 0.94--1.13), respectively, which was in accord with the result of the main analysis. Sensitivity analysis did not significantly change the summary RR (Supplementary Fig. 4 and Supplementary Table 9). No evidence of publication bias was detected using the Egger's test (*P* = 0.384) or Begg's test (*P* = 0.360).

Risk of new dialysis
--------------------

Nine trials were included in the analysis of IGC and the risk of new dialysis. The summary RR was 0.97 (95% CI, 0.84--1.11; *P* = 0.631) with low-to-moderate heterogeneity (*I* ^2^ = 29.1%; *P* = 0.186) (Supplementary Fig. 8 and Supplementary Table 4). Subgroup analysis revealed that for different ICU types of surgical, medical and mixed ICUs, the pooled RRs were 0.59 (95% CI, 0.40--0.88), 0.92 (95% CI, 0.74--1.14) and 1.06 (95% CI, 0.96--1.17), respectively, which was consistent with the result of the main analysis. Sensitivity analysis by excluding one study at a time did not alter the main result (Supplementary Fig. 5 and Supplementary Table 10). There was no evidence of publication bias using the Egger's test (*P* = 0.459) or Begg's test (*P* = 0.917).

Discussion
==========

In this meta-analysis of randomized controlled studies, neutral effects in the risk of 3- to 6-month mortality, short-term mortality, sepsis and new dialysis for critically ill patients with IGC intervention. However, significant increase in the risk of hypoglycemia was noted for those patients. These effects appeared to have similar trend in different ICU settings including surgical, medical and mixed ICUs.

Our findings are consistent with three previous meta-analyses and network meta-analyses of IGC and outcome in critically ill patient ([@bib42], [@bib43], [@bib44]), but included more outcome measures including risk of 3- to 6-month mortality, short-term mortality, hypoglycemia, sepsis and new dialysis with a relative larger sample size and more detailed sensitivity and trim-and-fill method analyses. To our knowledge, this is the most comprehensive meta-analysis summarizing results for the effects of IGC and adult critically ill patients treated in ICUs. The null effects for IGC intervention might result from the few studies included in this subset with limited sample size which should be further studied in the future.

The strengths of this updated meta-analysis were as follows. Firstly, we developed sensitive and comprehensive search strategies of all the electronic databases, enabling the process of literature screening and eligibility criteria more rigorously, and reporting the findings of meta-analyses more transparently. Second, we did not apply language or publication date limits during the search of the three major databases, making it less possible to miss some important publications which could be one major source of publication bias. Thirdly, at least two or three investigators independently selected trials, cross-checked them and identified the final included trials. Finally, one important strength was that we included five most commonly investigated and major outcomes to make the study one of the most comprehensive ones regarding this topic. Moreover, we conducted thorough subgroup analyses, sensitivity analyses and applied trim-and-filled method to test between-study heterogeneity and confirm the robustness of the results for each outcome, which made the results more reliable with the largest sample size ever involved.

This meta-analysis has some limitations. First, though low statistical heterogeneity for most of the meta-analyses was detected (with *I* ^2^ statistic less than 20% in four of five outcomes except risk of hypoglycemia), still we noted that the included patients were rather different among trials, including surgical ICUs, medical ICUs or mixed ones. Another potential limitation of this meta-analysis is the lack of patient-level data. There was variation in the type of insulin, the dose and mode of administration (subcutaneous vs infusion), the duration of follow-up and the combination of concomitant therapy, which we did not explore most of these factors with subgroup analyses due to the unavailability of the data. Thirdly, not all trials reported on all outcomes of interest, and some of the trials were not designed to measure these outcomes. However, this updated meta-analysis has been strengthened by the inclusion of all RCTs regarding this topic.

On the basis of this updated meta-analysis, we conclude that IGC offers no significant benefits for critically ill patients in terms of 3- to 6-month mortality, short-term mortality, sepsis and new dialysis, but adds the risk of hypoglycemia. We advocated that future well-designed RCTs in specific subgroups (eg. in diabetic or non-diabetic patients, in patients with different daily insulin dose, etc.) or with other study outcomes (such as cardiovascular related mortality) should be conducted.
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[^1]: BG, blood glucose; CG, conventional glucose control; ICU, intensive care unit; NA, not available; TG, intensive glucose control.

[^2]: CI, confidence interval; RR, relative risk.

[^3]: CI, confidence interval; RR, relative risk.
